We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-10.11%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$301M
AUM Growth
+$23.8M
Cap. Flow
+$67.7M
Cap. Flow %
22.49%
Top 10 Hldgs %
83.86%
Holding
26
New
5
Increased
13
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$29.5M
2
ALIM
Alimera Sciences
ALIM
+$13.2M
3
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$8.26M
4
EOLS icon
Evolus
EOLS
+$6.03M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$4.67M

Top Sells

Rank Stock Value
1
THRD
Third Harmonic Bio
THRD
+$13.4M
2
URGN icon
UroGen Pharma
URGN
+$4.64M
3
CSTL icon
Castle Biosciences
CSTL
+$1.26M
4
MXCT icon
MaxCyte
MXCT
+$825K
5
SCYX icon
SCYNEXIS
SCYX
+$280K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
URGN icon
26
UroGen Pharma
URGN
$2B
– –
-448,508
Closed -$4.64M
1
2

Similar funds

ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Stonepine Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Stonepine Capital Management held 26 positions worth $301M, up 8.6% from $277M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Stonepine Capital Management deployed $67.7M of net new capital in Q3 2023, opening 5 new positions and adding to 13 existing holdings. Its largest new stake was Alimera Sciences: 3,983,686 shares worth $12.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was MaxCyte, an estimated $825K trimmed.

  • Stonepine Capital Management's largest Q3 2023 buy was Alimera Sciences: 3,983,686 shares worth $12.3M.
  • Stonepine Capital Management added most to Amylyx Pharmaceuticals in Q3 2023, an estimated $29.5M increase.
  • Stonepine Capital Management's biggest Q3 2023 reduction was MaxCyte, cutting an estimated $825K.
  • Stonepine Capital Management fully exited Third Harmonic Bio in Q3 2023, selling an estimated $13.4M.
  • Stonepine Capital Management's ten largest holdings make up 84% of its $301M portfolio in Q3 2023.
  • Stonepine Capital Management opened 5 new positions and closed 3 in Q3 2023.
  • Stonepine Capital Management's portfolio value rose 8.6% quarter-over-quarter to $301M.

Based on Stonepine Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.